StockData
Legend Biotech Corp logo

Legend Biotech Corp (LEGN) income statement

LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 10, 2026Score 3/30
$16.25+0.14 (+0.87%)

Close on Nov 18, 2026Market cap $3.01BP/E –Yield –

Legend Biotech Corp income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
57.2%
Operating margin
-4.3%
Net margin
–
Return on equity, FY2025
–

Financial strength

Current ratio
3.04
Debt to equity
–
Debt to assets
–
Cash to current liabilities
166.7%

Valuation

P/E ratio
–
Price to sales
2.36
Price to book
–
Dividend yield
–

See a number that looks wrong?